Last updated: June 20, 2026
Propafenone hydrochloride is an established antiarrhythmic with a mature, generic-dominant US and EU footprint. Financial performance is constrained by low-cost generic competition, limited differentiation by formulation, and the aging of any remaining brand protections. Commercial upside is typically tied to (1) Rx volume stability in atrial and ventricular arrhythmia indications, (2) persistence of higher-cost branded legacy use in specific markets, and (3) any incremental formulation value (extended-release versus immediate-release) or geographic coverage.
How big is the propafenone hydrochloride market and what drives demand by indication?
Propafenone demand tracks prescribing for supraventricular arrhythmias and certain ventricular arrhythmias where class IC sodium-channel blockade is appropriate. In practice, use depends on guideline position, prescriber preference, and competing class IC or class III/other antiarrhythmics.
Key commercial demand drivers
- Indication fit: atrial fibrillation/flutter conversion and maintenance in selected patients; rhythm control strategies in supraventricular tachyarrhythmias; ventricular arrhythmia use is more constrained by safety profile and patient selection.
- Patient and prescriber selection: class IC drugs are often used when structural heart disease exclusions and contraindications allow.
- Dose-form preference: extended-release (ER) schedules can improve adherence and reduce daily dosing friction versus immediate-release (IR), affecting share within the molecule category.
- Substitution behavior: generic substitution is rapid where authorized equivalents exist, compressing price.
Demand volatility factors
- Guideline drift: changes in rhythm control vs rate control emphasis.
- Safety and monitoring practices: requirement patterns for ECG monitoring, proarrhythmia concern, and contraindication screening.
- Competitive substitution: amiodarone, sotalol, dofetilide, dronedarone, flecainide, and catheter ablation as alternatives.
Which propafenone formulations matter commercially: immediate-release vs extended-release?
Propafenone exists in IR and ER forms in major markets. Category share and revenue typically skew toward the form that aligns best with adherence needs and payer preferences.
Commercial consequence
- ER products often sustain a more stable price than IR during generic transitions when payers treat the formulation as a distinct prescribing choice (less substitution switching at the exact NDC level).
- IR products usually face faster price erosion once multiple generics are available.
How do reimbursement and payer rules shape net price?
Net revenue is usually driven by:
- Wholesale acquisition price (WAC) minus rebates and discounts (US PBM contracting).
- Formulary tiering that can shift a product from preferred to non-preferred.
- Switching incentives when an equivalent generic becomes the “lowest cost” option.
What is the financial trajectory for propafenone hydrochloride: brand history, generic transition, and revenue decay?
Propafenone hydrochloride has followed the typical lifecycle of an older antiarrhythmic: peak brand period followed by long generic dominance, with revenue now determined by low net-price competition rather than patent-based differentiation.
Trajectory pattern seen in mature, oral antiarrhythmics
- Early period: branded launch and physician adoption.
- Mid lifecycle: generic entrants reduce price and share for branded SKUs.
- Current lifecycle: revenue is sustained by continued Rx volume but with structurally lower margins and limited upside.
Typical revenue drivers today
- Channel mix: retail versus mail order affects dispensing volume stability.
- Formulary presence: a product’s formulary tier impacts volume.
- NDC-level competition: multiple AB-rated generics can fragment share.
What are the main cost and margin mechanics affecting the molecule’s profitability?
- Generic pricing is determined by competitive bidding and local market concentration among authorized manufacturers.
- Manufacturing scale and process efficiency are decisive given narrow gross margins typical of generics.
- Contracting and PBM rebates reduce net realizations further for non-preferred SKUs.
What patents protect propafenone hydrochloride in the US and how many are still relevant?
A complete, accurate patent estate mapping requires Orange Book and patent-register extraction by drug product, strength, and dosage form. Without that dataset in the record available here, the specific US patent numbers, assignees, and expiration dates for propafenone hydrochloride cannot be stated precisely.
What can be stated at a business level
- For older small-molecule drugs, the remaining exclusivity risk is usually concentrated in:
- Formulation patents (ER or specific crystalline/solid-state forms)
- Method-of-use patents (if any were added post-approval)
- Exclusivity attached to specific NDA/ANDA product generations, not the API broadly
Are there Orange Book-listed patents for propafenone hydrochloride today?
The Orange Book status for a specific US NDA/strength/dosage form determines whether new entrants face listed-patent barriers via Paragraph IV challenges. A product-level Orange Book listing cannot be reliably produced without the Orange Book record.
When does propafenone hydrochloride lose exclusivity and how long does market exclusivity last by geography?
Exclusivity for propafenone depends on:
- Whether the relevant US product is tied to a specific NDA and its listed patents
- Whether the EU market relies on Supplementary Protection Certificates (SPCs) or national exclusivity tied to specific formulations
- Patent term adjustments and terminal disclaimers that can shorten real-world coverage
A firm exclusivity timeline requires product-specific patent and regulatory event data.
US timing: how does FDA exclusivity interact with patent expiration?
In the US, generic entry timing is typically gated by:
- Patent expiration and any active stays from Paragraph IV litigation
- Any FDA exclusivity periods (5 years, 3 years for certain components, or 7 years for orphan, depending on the NDA history)
- Product-specific implementation changes that can trigger new Orange Book listings
Without the NDA/NDC and Orange Book entries, a date-specific answer cannot be provided accurately.
Which companies manufacture and market propafenone hydrochloride and how does the competitive landscape affect pricing?
The competitive landscape for mature generic molecules typically includes:
- Large generic manufacturers with scale in oral solids
- Multiple ANDA filers producing equivalent dosage forms
- Limited differentiation beyond ER vs IR and device/form factor
Business impact of fragmentation
- When many manufacturers compete, pricing reaches a floor.
- Revenue shifts among competitors based on:
- procurement contracts,
- inventory availability,
- lot release performance,
- and payer switching.
How does ER vs IR competition change market structure?
ER products can sustain marginally better economics if:
- fewer competitors file the exact ER dosage strength/formulation,
- substitution switching is slower due to NDC-level contracting,
- or prescribers anchor to specific ER products.
IR products typically face the most intense substitution pressure.
What Paragraph IV generic entry risks exist for propafenone hydrochloride?
Paragraph IV risk depends on the presence of Orange Book-listed patents for the specific propafenone product (NDA/strength/form). It also depends on whether litigation has already resolved via settlement or final judgment.
A complete Paragraph IV risk assessment cannot be built without:
- Orange Book patent listing set
- any known Paragraph IV actions
- docket outcomes
Without that dataset, assigning specific Paragraph IV risk is not supportable.
What patent litigation affects propafenone hydrochloride generics and settlements?
Patent litigation outcomes determine whether:
- generic launches are delayed by injunction or consent decree,
- or settlements allow “at-risk” launch for some products while others wait.
A litigation map requires court docket and settlement references per product.
Because no litigation record is included here, an accurate litigation and settlement summary cannot be produced.
What is the FDA regulatory status of propafenone hydrochloride: approved products, ANDAs, and labeling evolution?
Regulatory status for propafenone hydrochloride is reflected in:
- listed NDA(s) and ANDA(s)
- current labeling (indications, contraindications, warnings)
- any REMS or safety labeling updates
A precise regulatory status update requires the FDA Drugs@FDA and Orange Book record for propafenone hydrochloride product codes.
Without that, a date-specific regulatory narrative would be incomplete.
How does propafenone hydrochloride compare with alternative antiarrhythmics on market attractiveness?
Category comparison framework
- Pricing ceiling: older, generic-dominant agents usually have low pricing per script.
- Clinical positioning: agents that are more guideline-favored or used in broader populations can sustain volume even with low net prices.
- Safety profile and monitoring intensity: can constrain adoption but can also sustain a stable base if prescribers rely on experience.
Competitive substitutes
- Flecainide (class IC alternative for supraventricular arrhythmias)
- Amiodarone and dronedarone (class III with different safety/monitoring tradeoffs)
- Sotalol and dofetilide (class III alternatives)
- Catheter ablation reducing long-term drug use for certain arrhythmia pathways
Business consequence
- Propafenone’s market attractiveness typically depends on maintaining share within class IC use and protecting ER-specific preference where it exists.
What commercial strategies improve the financial trajectory for propafenone hydrochloride?
For generics and authorized successors, the financial trajectory is improved by operational and contracting execution more than IP innovation.
Actionable levers
- Target ER where prescribing patterns and payer contracting support differentiation at NDC level.
- Optimize procurement and maintain supply reliability to avoid volume loss during shortages.
- Contract with PBMs/MA plans for preferred positioning.
- Reduce COGS via scale and process standardization for oral solids.
- Maintain lot-level quality and reduce recalls to preserve channel trust.
Key Takeaways
- Propafenone hydrochloride is a mature antiarrhythmic with commercial performance driven mainly by generic competition, payer contracting, and formulation-specific market share (ER vs IR).
- The financial trajectory is typically characterized by post-brand revenue decline followed by low-margin stability rather than growth.
- A precise exclusivity, patent expiration, Paragraph IV risk, and litigation timeline cannot be stated without product-specific Orange Book and docket data for each NDA/strength/dosage form.
FAQs
- How do ER formulations of propafenone hydrochloride hold share better than immediate-release after generic entry?
- What payer contracting factors determine net price for generic antiarrhythmics like propafenone hydrochloride?
- How does catheter ablation utilization affect long-term prescription volume for propafenone hydrochloride in atrial arrhythmias?
- What are the main substitution risks between propafenone and flecainide in class IC rhythm-control strategies?
- How should manufacturers plan capacity and supply to avoid channel volume loss during antiarrhythmic generic competition?
References (APA)
- FDA. Drugs@FDA database. https://www.accessdata.fda.gov/scripts/cder/daf/
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
